Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics, Inc. develops allogeneic T-cell immunotherapies through an Epstein-Barr virus (EBV) T-cell platform for cancer and autoimmune disease programs. Company news centers on tabelecleucel, also referred to as tab-cel or EBVALLO, regulatory communications with the FDA, and collaboration activity with Pierre Fabre Pharmaceuticals for the EBV-positive post-transplant lymphoproliferative disease program.
Recurring updates also cover financial results, commercialization revenue, research and development spending, operational efficiency measures, milestone and royalty-related agreements, and equity-linked financing instruments such as warrants. Atara also reports on its inventory-based cell therapy approach, platform attributes that avoid T-cell receptor or HLA gene editing, and pipeline candidates including ATA3431 and ATA3219.
Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 8,000 restricted stock units to a newly hired employee. This stock award, approved by Atara's Compensation Committee, is part of the 2018 Inducement Plan, dated October 3, 2022. The units will vest over four years, with 25% vesting after the first year and the remaining in quarterly installments, contingent on ongoing employment. Atara continues to develop its T-cell immunotherapy platform aimed at treating serious diseases, including EBV-driven conditions.
Atara Biotherapeutics (NASDAQ: ATRA) has amended its collaboration agreement with Pierre Fabre, which includes a milestone payment of USD 30 million upon the European Commission's approval of the tab-cel® Marketing Authorization Application (MAA). The anticipated approval is on track for Q4 2022. Despite a reduction in some royalties, Atara maintains a significant double-digit royalty rate on future sales. The partnership aims to commercialize tab-cel® for EBV-positive cancers, expanding treatment options for patients in Europe and other emerging markets.
Atara Biotherapeutics (NASDAQ: ATRA) announced participation by CEO Pascal Touchon in a cell therapy panel at the Citigroup 17th Annual Biopharma Conference on September 7, 2022, at 6:40 a.m. PDT. The event will be accessible via a live webcast on the company's website, with an archived version available for 30 days post-event. Atara specializes in T-cell immunotherapy, focusing on EBV T-cell platforms to tackle cancer and autoimmune diseases. Their lead program is in Phase 3 development for EBV+ post-transplant lymphoproliferative disease.
Atara Biotherapeutics (ATRA) has reported its Q2 2022 financial results, achieving cash reserves of $331.3 million, an increase from $301.8 million in Q1 2022. The company plans to reduce its annual cash burn by over 20%, extending its cash runway into Q1 2024. Positive developments include FDA's recommended pathway for tab-cel's BLA filing without new trials and completion of the ATA188 Phase 2 EMBOLD study Interim Analysis. However, the termination of the Bayer collaboration will significantly reduce future revenues.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) has granted 82,756 restricted stock units and stock options for 98,701 shares to newly hired employees as part of its 2018 Inducement Plan, effective August 1, 2022. The stock units vest over four years, and the options have a ten-year term with an exercise price of $2.85 per share. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new staff. Atara is focused on T-cell immunotherapy and has multiple programs in clinical development targeting serious diseases.
Atara Biotherapeutics (Nasdaq: ATRA) announced that its CEO, Pascal Touchon, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 9:00 a.m. PDT. The presentation will focus on the company's innovative allogeneic Epstein-Barr virus (EBV) T-cell platform aimed at treating cancer and autoimmune diseases. A live webcast will be available on their website, with an archived replay accessible for 30 days post-event. Atara is advancing several therapies, including tab-cel® for EBV+ PTLD and ATA188 for multiple sclerosis.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its Q2 2022 financial results after the market closes on August 8, 2022. A live conference call and webcast will follow at 4:30 p.m. EDT to discuss results and corporate updates. The company is advancing T-cell immunotherapy using its allogeneic Epstein-Barr virus (EBV) platform, with lead programs in Phase 3 development targeting conditions like EBV+ PTLD and multiple sclerosis. Atara aims to provide off-the-shelf therapies for patients with high unmet medical needs.
Atara Biotherapeutics has announced that its Independent Data and Safety Monitoring Committee (IDSMC) recommended continuing the ATA188 Phase 2 study without adjusting the sample size. The IDSMC did not identify any safety concerns during its evaluation, focusing on the expanded disability status scale (EDSS) and biomarker data. The company achieved its target enrollment of 80 patients and anticipates sharing finalized results in October 2023.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced it will release results from the ATA188 Phase 2 EMBOLD Study Interim Analysis on July 12, 2022, after market close. The study focuses on tackling EBV antigens for potential multiple sclerosis therapy. Following the press release, a live conference call and webcast will occur at 5:00 p.m. EDT. Atara is recognized for its advancements in T-cell immunotherapy, with ongoing clinical programs targeting serious diseases, including solid tumors and autoimmune disorders.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the grant of 31,515 restricted stock units and stock options for 15,227 shares to newly hired employees as part of their 2018 Inducement Plan. The awards were approved by Atara's Compensation Committee and are designed to attract talent under Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with a 25% initial vest on the first anniversary. The stock options have a ten-year term and an exercise price of $8.30 per share, reflecting the stock's closing price on the grant date of July 1, 2022.